Burns : journal of the International Society for Burn Injuries
-
Randomized Controlled Trial
Effects of intravenous tranexamic acid on bleeding during burn surgery: A double-blinded randomized clinical trial.
Blood loss during burn surgery significantly contributes to morbidity and mortality. Tranexamic acid (TXA), an antifibrinolytic agent, is hypothesized to reduce intraoperative bleeding. This double-blinded, randomized clinical trial aimed to assess the efficacy of systemic TXA in severe burn patients (total body surface area [TBSA] > 20 %) undergoing surgery. ⋯ Results demonstrated significant reductions in blood loss (P = 0.043), total IV fluid volume (P = 0.021), OR time (P = 0.002), LOS (P = 0.0001), and transfusions (P = 0.024) in the TXA group. Notably, women and patients without inhalation injuries exhibited better responses to TXA treatment, and graft survival was lower in the TXA group. The study concludes that IV TXA administration during burn surgery can reduce bleeding, minimize IV fluid and blood transfusion needs, and shorten surgery duration, enhancing overall surgical outcomes.
-
Randomized Controlled Trial
Wireless Micro Current Stimulation (WMCS) therapy to enhance burn wound healing: A randomized clinical trial.
Pediatric burn injuries are often associated with significant morbidity, and require specialized care. The primary advantage of Wireless Micro Current Stimulation (WMCS) is the ability to deliver electric current without direct contact with the wound, which is particularly advantageous in the pediatric population and in those with wounds over multiple areas or over sensitive regions. ⋯ Our study shows statistically significant improvement in healing time with WMCS therapy, despite a two times higher average TBSA% in the WMCS group.